Contrasting Prime Medicine (NYSE:PRME) & Kymera Therapeutics (NASDAQ:KYMR) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Investment analysts at Citigroup initiated coverage on shares of Prime Medicine (NYSE:PRME – Get Free Report) in a research report issued on Friday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $10.00 price target on the stock. Citigroup’s target price points to a potential upside of 17.65% from the stock’s previous close. Several […]
Prime Medicine, Inc (NYSE:PRME) Receives $21 60 Consensus Price Target from Brokerages etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Prime Medicine (NYSE:PRME – Get Free Report) is one of 288 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Prime Medicine to similar companies based on the strength of its earnings, valuation, institutional ownership, risk, analyst recommendations, profitability and dividends. Insider and Institutional […]
Prime Medicine (NYSE:PRME – Get Free Report) is one of 288 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Prime Medicine to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk. Profitability […]